Drug Safety Update is essential reading for all healthcare professionals, bringing you the very latest information and advice to support the safer use of medicines.
- When reporting adverse drug reactions associated with biological medicines, such as biosimilar products or vaccines, it is important to provide the brand name and batch number. Products (biosimilar and reference) that have the same international non-proprietary name (INN) are not to be presumed identical, and there may be several different brands of a biological medicine for one particular condition (eg, different brands of influenza vaccines); furthermore, any concerns may be batch-specific.
Human papillomavirus vaccine Cervarix: safety review shows balance of risks and benefits remains clearly positive
A safety review conducted at the end of its routine use during the ongoing human papillomavirus immunisation programme has found that no new risks have been identified for Cervarix, and that the balance of its risks and benefits remains clearly positive. Cervarix was replaced in the programme by the HPV vaccine Gardasil▼ from September 2012.
Other information from the MHRA
Up to 3.5 CPD points can be claimed for this module.